$RLFTF RELIEF SELECTS CRO AND CDMO FOR RLF-100TM IN EUROPE
18 November 2020
European clinical assessment of RLF-100™ for the treatment of COVID-19 induced lung injury planned to begin in Q1 2021
Geneva, Switzerland, November 18, 2020 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"
, a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Syneos Health® (Nasdaq:SYNH), a leading global clinical research organization (CRO), to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications to be conducted in Europe. Relief has also selected AMRI, a global contract development and manufacturing organization (CDMO), who will provide aseptic fill/finish manufacturing of RLF-100TM at their Glasgow, UK, facility. European clinical assessment of RLF-100TM is slated to begin in Q1 2021.(cont'd)